APA

van Hout B. A., Bowman L., Zelinger D. J. & Simoons M. L. (19980716). Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. : European heart journal.

Chicago

van Hout B A, Bowman L, Zelinger D J and Simoons M L. 19980716. Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. : European heart journal.

Harvard

van Hout B. A., Bowman L., Zelinger D. J. and Simoons M. L. (19980716). Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. : European heart journal.

MLA

van Hout B A, Bowman L, Zelinger D J and Simoons M L. Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. : European heart journal. 19980716.